Quoin Pharmaceuticals (QNRX) 6-K/A 11 Feb 21 2020 Q2 Current report (foreign) (amended) Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Jun. 30, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	Cellect Biotechnology Ltd.
Entity Central Index Key	0001671502
Amendment Flag	true
Amendment Description	Amendment
Current Fiscal Year End Date	--12-31
Document Type	6-K/A
Document Fiscal Period Focus	Q2
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Entity File Number	001-37846

Consolidated Balance Sheets

Consolidated Balance Sheets ₪ in Thousands, $ in Thousands	Jun. 30, 2020USD ($)	Jun. 30, 2020ILS (₪)	Dec. 31, 2019ILS (₪)
CURRENT ASSETS:
Cash and cash equivalents | ₪		₪ 24,269	₪ 18,106
Other receivables | ₪		960	469
CURRENT ASSETS | ₪		25,229	18,575
LONG-TERM ASSETS:
Restricted cash | ₪		330	328
Right of use - Assets under operating lease | ₪		908	1,035
Other long term assets | ₪		76	94
Property, plant and equipment, net | ₪		1,087	1,288
Non-current assets | ₪		2,401	2,745
Assets | ₪		27,630	21,320
CURRENT LIABILITIES:
Trade payables | ₪		420	158
Other payables | ₪		2,158	3,080
Current maturities of lease liability | ₪		416	396
Current liabilities | ₪		2,994	3,634
NON CURRENT LIABILITIES:
Warrants to ADS | ₪		2,307	2,172
Lease liabilities | ₪		538	677
Non current Liabilities | ₪		2,845	2,849
SHAREHOLDERS' EQUITY :
Ordinary shares of no par value: Authorized: 500,000,000 shares at December 31, 2019 and June 30, 2020 (unaudited); Issued and outstanding: 224,087,799* at December 31, 2019; and 390,949,079* at June 30, 2020(unaudited). | ₪
Additional paid-in capital | ₪		126,839	108,598
Share-based payments | ₪		16,597	16,528
Treasury shares | ₪		(9,425)	(9,425)
Accumulated deficit | ₪		(112,220)	(100,864)
Equity | ₪		21,791	14,837
Equity and liabilities | ₪		₪ 27,630	₪ 21,320
U.S. dollars [Member]
CURRENT ASSETS:
Cash and cash equivalents | $	$ 7,002
Other receivables | $	277
CURRENT ASSETS | $	7,279
LONG-TERM ASSETS:
Restricted cash | $	95
Right of use - Assets under operating lease | $	262
Other long term assets | $	22
Property, plant and equipment, net | $	314
Non-current assets | $	693
Assets | $	7,972
CURRENT LIABILITIES:
Trade payables | $	121
Other payables | $	622
Current maturities of lease liability | $	120
Current liabilities | $	863
NON CURRENT LIABILITIES:
Warrants to ADS | $	666
Lease liabilities | $	155
Non current Liabilities | $	821
SHAREHOLDERS' EQUITY :
Ordinary shares of no par value: Authorized: 500,000,000 shares at December 31, 2019 and June 30, 2020 (unaudited); Issued and outstanding: 224,087,799* at December 31, 2019; and 390,949,079* at June 30, 2020(unaudited). | $
Additional paid-in capital | $	36,595
Share-based payments | $	4,789
Treasury shares | $	(2,719)
Accumulated deficit | $	(32,377)
Equity | $	6,288
Equity and liabilities | $	$ 7,972

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares		Jun. 30, 2020	Dec. 31, 2019
Statement of financial position [abstract]
Ordinary shares, par value
Ordinary shares, authorized		500,000,000	500,000,000
Ordinary shares, issued	[1]	390,949,079	224,087,799
Ordinary shares, outstanding	[1]	390,949,079	224,087,799
Treasury shares		2,641,693	2,641,693
[1]	Net of 2,641,693 treasury shares of the Company held by the Company.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) ₪ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2020ILS (₪)₪ / sharesshares	Jun. 30, 2019ILS (₪)₪ / sharesshares
Statement Line Items [Line Items]
Research and development expenses | ₪		₪ 2,901	₪ 7,086
General and administrative expenses | ₪		4,703	5,064
Total operating expenses | ₪		7,604	12,150
Operating loss | ₪		7,604	12,150
Financial income | ₪		(98)	(7,111)
Financial expenses | ₪		3,850	880
Total comprehensive loss | ₪		₪ 11,356	₪ 5,919
Loss per share:
Basic and diluted loss per share | ₪ / shares		₪ 0.034	₪ 0.029
Weighted average number of shares outstanding used to compute basic and diluted loss per share | shares	338,182,275	338,182,275	200,942,871
U.S. dollars [Member]
Statement Line Items [Line Items]
Research and development expenses | $	$ 837
General and administrative expenses | $	1,356
Total operating expenses | $	2,193
Operating loss | $	2,193
Financial income | $	(28)
Financial expenses | $	1,111
Total comprehensive loss | $	$ 3,276
Loss per share:
Basic and diluted loss per share | $ / shares	$ 0.010
Weighted average number of shares outstanding used to compute basic and diluted loss per share | shares	338,182,275	338,182,275

Statements of Changes in Equity

Statements of Changes in Equity ₪ in Thousands, $ in Thousands	Share capitalILS (₪)	Share capitalU.S. dollarsUSD ($)	Additional paid-in capitalILS (₪)	Additional paid-in capitalU.S. dollarsUSD ($)	Treasury sharesILS (₪)	Treasury sharesU.S. dollarsUSD ($)	Share based payments optionILS (₪)	Share based payments optionU.S. dollarsUSD ($)	Accumulated deficitILS (₪)	Accumulated deficitU.S. dollarsILS (₪)	ILS (₪)	U.S. dollarsUSD ($)
Balance at Dec. 31, 2018			₪ 95,085		₪ (9,425)		₪ 12,319		₪ (84,056)		₪ 13,923
Issuance of ADS, net of issue costs			13,505				1,509				15,014
Share-based payment			8				2,700				2,708
Total comprehensive loss									(16,808)		(16,808)
Balance at Dec. 31, 2019			108,598		(9,425)		16,528		(100,864)		14,837
Issuance of ADS, net of issue costs			9,194								9,194
Share-based payment							829				829
Exercise of options and warrants into shares			9,047				(760)				8,287
Total comprehensive loss									(11,356)		(11,356)
Balance at Jun. 30, 2020			₪ 126,839	$ 36,595	₪ (9,425)	$ (2,719)	₪ 16,597	$ 4,789	₪ (112,220)	₪ (32,377)	₪ 21,791	$ 6,288

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) ₪ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)	Jun. 30, 2020ILS (₪)	Jun. 30, 2019ILS (₪)
Cash flows from operating activities:
Total comprehensive loss | ₪		₪ (11,356)	₪ (5,919)
Adjustments to profit or loss items:
Exchange rate difference | ₪		5
Net financing expenses | ₪		37	815
Loss (gain) from revaluation of financial assets presented at fair value through profit or loss | ₪			6
Depreciation | ₪		170	192
Share-based payment | ₪		829	529
Changes in fair value of warrants | ₪		3,807	(8,442)
Interest received during the period | ₪		35	(46)
Adjustments to profit or loss items | ₪		4,883	(6,946)
Changes in asset and liability items:
Decrease (increase) in other receivables | ₪		(473)	126
Decrease (increase) in other long-term assets | ₪			19
Decrease in trade and other payables | ₪		(753)	(715)
Decrease in right-of-use assets | ₪		183	314
Operating activities for changes in asset and liability | ₪		(1,043)	(256)
Cash paid and received during the period for:
Net cash used in operating activities | ₪		(7,516)	(13,121)
Cash flows from investing activities:
Restricted cash, net | ₪		(2)
Sale of property, plant and equipment, net | ₪		34
Purchase of property, plant and equipment, net | ₪		(3)	(120)
Net cash provided (used in) investing activities | ₪		29	(120)
Cash flows from financing activities:
Exercise of share options | ₪		4,707
Issuance of share capital and warrants, net of issue costs | ₪		9,194	23,723
Leases liabilities | ₪		(212)	(278)
Net cash provided by financing activities | ₪		13,689	23,445
Exchange differences on balances of cash and cash equivalents | ₪		(39)	(769)
Increase in cash and cash equivalents | ₪		6,163	9,435
Cash and cash equivalents at beginning of period | ₪		18,106	17,809
Cash and cash equivalents at end of period | ₪		24,269	27,244
(a) Non-cash activities:
Issuance expenses related to fund raising | ₪		₪ 93	₪ 164
U.S. dollars [Member]
Cash flows from operating activities:
Total comprehensive loss | $	$ (3,276)
Adjustments to profit or loss items:
Exchange rate difference | $	1
Net financing expenses | $	11
Loss (gain) from revaluation of financial assets presented at fair value through profit or loss | $
Depreciation | $	49
Share-based payment | $	239
Changes in fair value of warrants | $	1,098
Interest received during the period | $	10
Adjustments to profit or loss items | $	1,408
Changes in asset and liability items:
Decrease (increase) in other receivables | $	(136)
Decrease (increase) in other long-term assets | $
Decrease in trade and other payables | $	(217)
Decrease in right-of-use assets | $	53
Operating activities for changes in asset and liability | $	(300)
Cash paid and received during the period for:
Net cash used in operating activities | $	(2,168)
Cash flows from investing activities:
Restricted cash, net | $	(1)
Sale of property, plant and equipment, net | $	10
Purchase of property, plant and equipment, net | $	(1)
Net cash provided (used in) investing activities | $	8
Cash flows from financing activities:
Exercise of share options | $	1,358
Issuance of share capital and warrants, net of issue costs | $	2,652
Leases liabilities | $	(61)
Net cash provided by financing activities | $	3,949
Exchange differences on balances of cash and cash equivalents | $	(11)
Increase in cash and cash equivalents | $	1,778
Cash and cash equivalents at beginning of period | $	5,224
Cash and cash equivalents at end of period | $	7,002
(a) Non-cash activities:
Issuance expenses related to fund raising | $	$ 27

General

General	6 Months Ended
	Jun. 30, 2020
General [Abstract]
GENERAL	NOTE 1: GENERAL a. Cellect Biotechnology Ltd. (formerly Cellect Biomed Ltd.) (the "Company" or "Cellect") was incorporated in Israel. Cellect's American Depository Shares ("ADSs") and certain warrants to purchase ADSs are listed for trading on the NASDAQ Capital Market. Each ADS represents 100 ordinary shares. Cellect and its subsidiary, Cellect Biotherapeutics Ltd. (the "Subsidiary") are engaged in the development of an innovative, unique technology that enables the biological filtering and commercialization of stem cells. These financial statements have been prepared in a condensed format as of June 30, 2020, and for the six months then ended ("interim consolidated financial statements"). These financial statements should be read in conjunction with the Company's annual financial statements as of December 31, 2019, and for the year then ended and accompanying notes ("annual consolidated financial statements"). On May 8, 2018, the Subsidiary established a fully owned US subsidiary named Cellect Biotech, Inc (the "US Subsidiary"). This company was formed to engage in business development operations of the group. from June 2019, there is no activity in the US Subsidiary. b. On May 16, 2019 the Company announced it's plans to explore strategic alternatives focused on maximizing shareholder value. Potential strategic alternatives that may be evaluated include, but are not limited to, an acquisition, merger, business combination, in-licensing, or other strategic transaction involving the Company or its assets. On March 4, 2020 the Company reported the signing of two Letters of Intent (LOIs), one is a strategic commercial agreement which is binding, subject to reaching definitive agreement, and the other is contemplating a full merger. c. Going Concern The accompanying financial statements have been prepared in conformity with International Financial Reporting Standards (IFRS), assuming that the Company will continue to operate as a going concern. During the period ended June 30, 2020, the Company incurred total comprehensive loss of NIS 11,356 ($3,276) and had negative cash flows from operating activities of NIS 7,516 ($2,168). In addition, the Company had an accumulated deficit of NIS 112,220 ($32,377) at June 30, 2020. The Company's activities since inception have consisted of raising capital and performing research and development activities. As of June 30, 2020, principal commercial operations have not commenced. Successful completion of the Company's development programs and, ultimately, the attainment of profitable operations, if any, are dependent on future events, including, among other things, its ability to obtain marketing approval from regulatory authorities and access potential markets, secure financing, develop a customer base, attract, retain and motivate qualified personnel and develop strategic alliances. Although currently the company has sufficient funds to operate in the next 18 months, in order to reach profitability, the company will need to raise additional funds and there is no assurance that the company will be able to do so. The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need, among other things, to complete its research and development efforts and clinical and regulatory activities. These activities may take several years and will require significant operating and capital expenditures in the foreseeable future. There can be no assurance that these activities will be successful. If the Company is not successful in these activities it could delay, limit, reduce or terminate preclinical studies, clinical trials or other research and development activities. To fund its capital needs, the Company plans to raise funds through equity or debt financings or other sources, such as strategic partnerships and alliance and licensing arrangements, and in the long term, from the proceeds from sales. Additional funds may not be available when the Company needs them, on terms that are acceptable to it, or at all. These matters raise substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would result if the Company was unable to continue as a going concern.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2: SIGNIFICANT ACCOUNTING POLICIES a. Interim Financial Statements: The accompanying consolidated balance sheet as of June 30, 2020, the consolidated statements of comprehensive loss and the consolidated statements of cash flows for the six months ended June 30, 2020 and 2019, as well as the statement of changes in shareholders' equity for the six months ended June 30, 2020, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the IFRS The accompanying unaudited interim financial statements should be read in conjunction with the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission (the "SEC") on April 3, 2020, as amended by Form 20-F/A filed with the SEC on August 4, 2020. The interim consolidated financial statements have been prepared in accordance with IAS 34, "Interim Financial Reporting". The significant accounting policies applied in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the annual consolidated financial statements, except as described below: b. Estimates and assumptions: The preparation of the Company's financial statements requires management to make estimates and assumptions that influence application of the accounting policies and on the reported amounts of assets, liabilities, and expenses. Changes in accounting estimates are The key assumptions made in the financial statements concerning uncertainties at the ● Determining the fair value of share-based transactions: The fair value of share-based transactions is determined upon initial recognition using acceptable option pricing models. The model is based on per-share price data and the exercise price and assumptions regarding expected volatility, expected life, expected dividend and risk-free interest rate. c. Leases The Company has adopted IFRS 16 retrospectively from January 1, 2019 but has not restated comparative figures for the year ended December 31, 2018 reporting period, as permitted under the modified retrospective approach. Upon the initial adoption of the new standard the Company measured the right-of-use asset at an amount equal to the lease liability, as measured on the transition date. d. Convenience translation into U.S. dollars: The consolidated financial statements as of June 30, 2020 and for the six months then ended have been translated into U.S. dollars using the exchange rate of the U.S. dollar as of June 30, 2020 (U.S. $1.00 = NIS 3.466). The translation was made solely for convenience purposes. The dollar amounts presented in these financial statements should not be construed as representing amounts that are receivable or payable in dollars or convertible into dollars, unless otherwise indicated.

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	NOTE 3: Leases The movements in right-of use assets and lease liabilities are reported in the following tables: Right-of-use assets Offices Vehicles Total Cost Balance as of January 1, 2020 988 47 1,035 Additions during the year - 56 56 Depreciation expense (165 ) (18 ) (183 ) Balance as of June 30, 2020 823 85 908 Lease liabilities Offices Vehicles Total Cost Balance as of January 1, 2020 1,027 46 1,073 Additions during the year - 56 56 Lease expense 30 7 37 Payments (185 ) (27 ) (212 ) Balance as of June 30, 2020 872 82 954

Equity

Equity	6 Months Ended
	Jun. 30, 2020
Disclosure of fair value measurement of equity [abstract]
EQUITY	NOTE 4: EQUITY a. Changes in share capital: Number of shares Balance at January 1, 2019 (audited) *) 130,414,799 Issuance of shares and warrants 93,673,000 Balance at December 31, 2019 (audited) *) 224,087,799 Issuance of shares and warrants 166,861,280 Balance at June 30, 2020 (unaudited) *) 390,949,079 *) Net of 2,641,693 treasury shares of the Company, held by the Company. 1. On February 12, 2019, the Company sold to certain institutional investors an aggregate of 1,889,000 units, each consisting of (i) one ADS, and (ii) one warrant to purchase one ADS, at a public offering price of $1.50 per unit ($7.5 after split), and (b) 2,444,650 pre-funded units, each consisting of (i) one prefunded warrant to purchase one ADS, and (ii) one warrant, at a public offering price of $1.49 per Pre-funded unit. In connection with the offering, the Company granted the underwriters a 45-day option to purchase up to an additional 650,070 ADSs and/or 650,070 warrants to purchase up to an additional 650,070 ADSs. The underwriters partially exercised their over-allotment option to purchase an aggregate of 350,000 additional ADS and additional warrants to purchase 650,070 ADSs. Subsequently, of the pre-funded warrants issued, the Company issued 2,444,650 ADSs upon exercise of pre-funded warrants. The Company raised gross proceeds of NIS 25,422 (NIS 20,796 net of all issuance costs in the amount of NIS 4,626, including share-based awards granted). An amount of NIS 13,505 out of the consideration was related to the ADSs and classified as equity component, while an amount of NIS 8,999 was related to the fair value of the non-tradable Warrants and was classified as a liability. Since the warrant exercise price is in US dollars, which is not the Company's functional currency, the unregistered warrants to purchase ADS were classified as a financial liability at fair value and are marked to market through profit or loss in accordance with IAS 32. The underwriters' unlisted warrants were classified as a share-based payment transaction in accordance with IFRS 2 and netted off the total consideration as issuance cost. Furthermore, the Company issued to the underwriters unlisted warrants to purchase 109,642 ADSs at an exercise price of $7.5 per warrant and exercisable for a period of five years. The underwriters' unlisted warrants were classified as a share-based payment transaction in accordance with IFRS 2 and netted off the total consideration as issuance cost. On May 12, 2020 the Company entered into warrant exercise agreements with several investors. Under the terms of the agreement, in consideration of exercising 534,160 of the warrants, the exercise price per warrants was reduced to $2.75 per ADS. The 534,160 of the warrants were exercised resulting in gross proceeds to the Company of NIS 5,204 (NIS 4,591 net of issuance costs in the amount of NIS 613). In addition, the Company decided to reduce the exercise price of all warrants issued in February 2019, to $2.75 per ADS, from original exercise price per ADS of $7.5. The change in terms (i.e., reduction in the exercise price) of the warrants, classified as financial liability, resulted in an increase in the fair value of the warrants in a total amount of NIS 3,807. This amount was recorded as finance expenses. The change in terms of the warrants classified as equity was not affecting the results of operations but rather treated as classification within shareholders' equity. 2. On January 7, 2020, the Company sold to certain institutional investors aggregate of 1,000,000 ADSs in a registered direct offering at a purchase price of $3 per ADS. 3. On May 20, 2019, the board of directors approved a grant to a consultant of 672,264 warrants, exercisable for 672,264 ADSs of the Company at an exercise price of USD 0.01 per ADS. On January 31, 2020, the warrants were exercised.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2020
Share-Based Compensation [Abstract]
SHARE-BASED COMPENSATION	NOTE 5: SHARE-BASED COMPENSATION a. In February 2014, the Company's board of directors adopted an Employee Shares Incentive Plan (the "2014 Plan"). Under the 2014 Plan, options may be granted to employees, officers, directors, consultants, advisers and service providers of the Company. On June 20, 2019, the board of directors approved an increase to the unlisted option pool of 20,000,000 options. As a result, the Company has a total of 37,100,000 unlisted options in the pool. b. Activity during the period: The table below includes the number of share options, and the weighted average of their exercise prices: December 31, 2019 (audited) June 30, 2020 (unaudited) Number of options Weighted average exercise price Number of options Weighted average exercise price NIS NIS Outstanding at beginning of period 13,014,147 1.18 22,093,504 0.59 Options forfeited (4,556,865 ) 0.70 (58,438 ) 0.25 Option expired (671,438 ) 1.21 (325,001 ) 0.49 Granted 14,307,660 0.12 6,300,000 0.08 Outstanding at end of period 22,093,504 0.59 28,010,065 0.48 Options exercisable at the end of the period 13,730,238 7.8 21,337,751 8.0 c. The following table summarizes information about the assumptions for measuring the fair value of the options under the Black-Scholes option pricing model for the periods ended December 31, 2019 and June 30, 2020, is as follows: 2019 2020 Dividend yield (%) 0 0 Expected volatility of the share prices (%) 77.75 % 84.54%-87.53% Risk-free interest rate (%) 2.14 % 0.75%-1.85% Expected life of share options (years) 10 10 According to the data above, the fair value of options granted in the

Contingent Liabilities and Comm

Contingent Liabilities and Commitments	6 Months Ended
	Jun. 30, 2020
Contingent Liabilities and Commitments [Abstract]
CONTINGENT LIABILITIES AND COMMITMENTS	NOTE 6: CONTINGENT LIABILITIES AND COMMITMENTS Liens: The Company provided a NIS 51 restricted bank deposit to secure credit card payments. The Company provided a NIS 163 restricted bank deposit to secure the rent payment.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Significant Accounting Policies [Abstract]
Interim Financial Statements	a. Interim Financial Statements: The accompanying consolidated balance sheet as of June 30, 2020, the consolidated statements of comprehensive loss and the consolidated statements of cash flows for the six months ended June 30, 2020 and 2019, as well as the statement of changes in shareholders' equity for the six months ended June 30, 2020, are unaudited. These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the IFRS The accompanying unaudited interim financial statements should be read in conjunction with the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission (the "SEC") on April 3, 2020, as amended by Form 20-F/A filed with the SEC on August 4, 2020. The interim consolidated financial statements have been prepared in accordance with IAS 34, "Interim Financial Reporting". The significant accounting policies applied in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the annual consolidated financial statements, except as described below:
Estimates and assumptions	b. Estimates and assumptions: The preparation of the Company's financial statements requires management to make estimates and assumptions that influence application of the accounting policies and on the reported amounts of assets, liabilities, and expenses. Changes in accounting estimates are The key assumptions made in the financial statements concerning uncertainties at the ● Determining the fair value of share-based transactions: The fair value of share-based transactions is determined upon initial recognition using acceptable option pricing models. The model is based on per-share price data and the exercise price and assumptions regarding expected volatility, expected life, expected dividend and risk-free interest rate.
Leases	c. Leases The Company has adopted IFRS 16 retrospectively from January 1, 2019 but has not restated comparative figures for the year ended December 31, 2018 reporting period, as permitted under the modified retrospective approach. Upon the initial adoption of the new standard the Company measured the right-of-use asset at an amount equal to the lease liability, as measured on the transition date.
Convenience translation into U.S. dollars	d. Convenience translation into U.S. dollars: The consolidated financial statements as of June 30, 2020 and for the six months then ended have been translated into U.S. dollars using the exchange rate of the U.S. dollar as of June 30, 2020 (U.S. $1.00 = NIS 3.466). The translation was made solely for convenience purposes. The dollar amounts presented in these financial statements should not be construed as representing amounts that are receivable or payable in dollars or convertible into dollars, unless otherwise indicated.

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of right-of-use assets	Offices Vehicles Total Cost Balance as of January 1, 2020 988 47 1,035 Additions during the year - 56 56 Depreciation expense (165 ) (18 ) (183 ) Balance as of June 30, 2020 823 85 908
Schedule of lease liabilities	Offices Vehicles Total Cost Balance as of January 1, 2020 1,027 46 1,073 Additions during the year - 56 56 Lease expense 30 7 37 Payments (185 ) (27 ) (212 ) Balance as of June 30, 2020 872 82 954

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2019
Disclosure of fair value measurement of equity [abstract]
Schedule of changes in share capital	Number of shares Balance at January 1, 2019 (audited) *) 130,414,799 Issuance of shares and warrants 93,673,000 Balance at December 31, 2019 (audited) *) 224,087,799 Issuance of shares and warrants 166,861,280 Balance at June 30, 2020 (unaudited) *) 390,949,079 *) Net of 2,641,693 treasury shares of the Company, held by the Company.

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Share-Based Compensation [Abstract]
Schedule of number of share options and weighted average exercise prices	December 31, 2019 (audited) June 30, 2020 (unaudited) Number of options Weighted average exercise price Number of options Weighted average exercise price NIS NIS Outstanding at beginning of period 13,014,147 1.18 22,093,504 0.59 Options forfeited (4,556,865 ) 0.70 (58,438 ) 0.25 Option expired (671,438 ) 1.21 (325,001 ) 0.49 Granted 14,307,660 0.12 6,300,000 0.08 Outstanding at end of period 22,093,504 0.59 28,010,065 0.48 Options exercisable at the end of the period 13,730,238 7.8 21,337,751 8.0
Schedule of fair value of options under black-scholes	2019 2020 Dividend yield (%) 0 0 Expected volatility of the share prices (%) 77.75 % 84.54%-87.53% Risk-free interest rate (%) 2.14 % 0.75%-1.85% Expected life of share options (years) 10 10

General (Details)

General (Details) ₪ in Thousands, $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)shares	Jun. 30, 2020ILS (₪)shares	Jun. 30, 2019ILS (₪)	Jun. 30, 2020ILS (₪)	Dec. 31, 2019ILS (₪)
General (Textual)
Total comprehensive loss | ₪		₪ 11,356
Negative cash flows from operating activities | ₪		₪ (7,516)	₪ (13,121)
Accumulated deficit | ₪				₪ (112,220)	₪ (100,864)
ADS [Member]
General (Textual)
Aggregate of ordinary shares | shares	100	100
U.S. dollars [Member]
General (Textual)
Total comprehensive loss | $	$ 3,276
Negative cash flows from operating activities | $	(2,168)
Accumulated deficit | $	$ (32,377)

Significant Accounting Polici_3

Significant Accounting Policies (Details)	6 Months Ended
	Jun. 30, 2020
Significant Accounting Policies (Textual)
Description of translated exchange rate	The consolidated financial statements as of June 30, 2020 and for the six months then ended have been translated into U.S. dollars using the exchange rate of the U.S. dollar as of June 30, 2020 (U.S. $1.00 = NIS 3.466). The translation was made solely for convenience purposes.

Leases (Details)

Leases (Details) ₪ in Thousands	6 Months Ended
	Jun. 30, 2020ILS (₪)
Cost
Balance as of January 1, 2020	₪ 1,035
Additions during the year	56
Depreciation expense	(183)
Balance as of June 30, 2020	908
Offices [Member]
Cost
Balance as of January 1, 2020	988
Additions during the year
Depreciation expense	(165)
Balance as of June 30, 2020	823
Vehicles [Member]
Cost
Balance as of January 1, 2020	47
Additions during the year	56
Depreciation expense	(18)
Balance as of June 30, 2020	₪ 85

Leases (Details 1)

Leases (Details 1) ₪ in Thousands	6 Months Ended
	Jun. 30, 2020ILS (₪)
Cost
Balance as of January 1, 2020	₪ 1,073
Additions during the year	56
Lease expense	37
Payments	(212)
Balance as of June 30, 2020	954
Offices [Member]
Cost
Balance as of January 1, 2020	1,027
Additions during the year
Lease expense	30
Payments	(185)
Balance as of June 30, 2020	872
Vehicles [Member]
Cost
Balance as of January 1, 2020	46
Additions during the year	56
Lease expense	7
Payments	(27)
Balance as of June 30, 2020	₪ 82

Equity (Details)

Equity (Details) - shares		6 Months Ended	12 Months Ended
		Jun. 30, 2020	Dec. 31, 2019
Disclosure of fair value measurement of equity [abstract]
Balance, Beginning	[1]	224,087,799	130,414,799
Issuance of shares and warrants		166,861,280	93,673,000
Balance, Ending	[1]	390,949,079	224,087,799
[1]	Net of 2,641,693 treasury shares of the Company, held by the Company.

Equity (Details Textual)

Equity (Details Textual) - ILS (₪) ₪ / shares in Units, ₪ in Thousands	May 12, 2020	Jan. 07, 2020	Feb. 12, 2019	May 20, 2019	Feb. 28, 2019	Jun. 30, 2020	Dec. 31, 2019
Equity (Textual)
ADS shares, description	The 534,160 of the warrants were exercised resulting in gross proceeds to the Company of NIS 5,204 (NIS 4,591 net of issuance costs in the amount of NIS 613).
Warrants exercised	534,160
Treasury shares						2,641,693	2,641,693
Number of shares investors		1,000,000
Direct offering		₪ 3
Gross proceeds		₪ 10,410
Proceeds net of issuance costs		9,194
Fair value of the warrants						₪ 3,807
Warrants exercisable term			5 years
Warrant exercise price	₪ 2.75		₪ 7.5		₪ 2.75
Purchase of unlisted warrants			109,642
Description of underwritten public offering			The Company sold to certain institutional investors an aggregate of 1,889,000 units, each consisting of (i) one ADS, and (ii) one warrant to purchase one ADS, at a public offering price of $1.50 per unit ($7.5 after split), and (b) 2,444,650 pre-funded units, each consisting of (i) one prefunded warrant to purchase one ADS, and (ii) one warrant, at a public offering price of $1.49 per Pre-funded unit. In connection with the offering, the Company granted the underwriters a 45-day option to purchase up to an additional 650,070 ADSs and/or 650,070 warrants to purchase up to an additional 650,070 ADSs. The underwriters partially exercised their over-allotment option to purchase an aggregate of 350,000 additional ADS and additional warrants to purchase 650,070 ADSs. Subsequently, of the pre-funded warrants issued, the Company issued 2,444,650 ADSs upon exercise of pre-funded warrants. The Company raised gross proceeds of NIS 25,422 (NIS 20,796 net of all issuance costs in the amount of NIS 4,626, including share-based awards granted). An amount of NIS 13,505 out of the consideration was related to the ADSs and classified as equity component, while an amount of NIS 8,999 was related to the fair value of the non-tradable Warrants and was classified as a liability.
Original exercise price per ADS					₪ 7.5
Issuance costs in the amount of NIS		₪ 1,216
Description of warrant exercised				The board of directors approved a grant to a consultant of 672,264 warrants, exercisable for 672,264 ADSs of the Company at an exercise price of USD 0.01 per ADS. On January 31, 2020, the warrants were exercised.

Share-Based Compensation (Detai

Share-Based Compensation (Details) - ₪ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Share-Based Compensation [Abstract]
Number of options, Outstanding at beginning of period	22,093,504	13,014,147
Number of options, Options forfeited	(58,438)	(4,556,865)
Number of options, Option expired	(325,001)	(671,438)
Number of options, Granted	6,300,000	14,307,660
Number of options, Outstanding at end of period	28,010,065	22,093,504
Options exercisable at the end of the period	21,337,751	13,730,238
Weighted average exercise price, Outstanding at beginning of period	₪ 0.59	₪ 1.18
Weighted average exercise price, Options forfeited	0.25	0.70
Weighted average exercise price, Option Expired	0.49	1.21
Weighted average exercise price, Granted	0.08	0.12
Weighted average exercise price, Outstanding at end of period	0.48	0.59
Options exercisable at the end of the period	₪ 8	₪ 7.8

Share-Based Compensation (Det_2

Share-Based Compensation (Details 1)	6 Months Ended	12 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Schedule of fair value of options under black-scholes [Abstract]
Dividend yield (%)	0.00%	0.00%
Expected volatility of the share prices (%)		77.75%
Risk-free interest rate (%)		2.14%
Expected life of share options (years)	10 years	10 years
Bottom of range [member]
Schedule of fair value of options under black-scholes [Abstract]
Expected volatility of the share prices (%)	84.54%
Risk-free interest rate (%)	0.75%
Top of range [member]
Schedule of fair value of options under black-scholes [Abstract]
Expected volatility of the share prices (%)	87.53%
Risk-free interest rate (%)	1.85%

Share-Based Compensation (Det_3

Share-Based Compensation (Details Textual) - ILS (₪) ₪ in Thousands	1 Months Ended	6 Months Ended	12 Months Ended
	Jun. 20, 2019	Jun. 30, 2020	Dec. 31, 2019
Share-Based Compensation (Textual)
Unlisted option pool	37,100,000
Fair value of options, grant		₪ 481	₪ 1,275
Board of Directors [Member]
Share-Based Compensation (Textual)
Unlisted option pool	20,000,000

Contingent Liabilities and Co_2

Contingent Liabilities and Commitments (Details) ₪ in Thousands	Jun. 30, 2020ILS (₪)
Contingent Liabilities and Commitments (Textual)
Restricted bank deposit to secure credit card payments	₪ 51
Restricted bank deposit to secure the rent payment	₪ 163